Biopharma · FDA Approvals · Stock
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to p…
Assets on file: HT-001
Dated catalysts for RKTO, including recently decided ones.
Every first-hand event for RKTO, newest first.
Rocket One (RKTO) ends HT-001 Phase 2a early after positive interim efficacy
Hoth Therapeutics ended its Phase 2a trial of topical HT-001 (aprepitant) early due to strong interim efficacy and safety data in treating EGFR inhibitor-associated skin toxicity. The company will seek FDA feedback on a potential Phase 3/pivotal program design, endpoints, and registration pathway. HT-001 remains unapproved and investigational.
Companies in the same sector closest to RKTO in market value.